Drug
Daromun clinical trials
- studies test it
- 6
- open now
- 6
- in phase 3
- 1
- first study started
- 2018
Keep track of what changes. Save the daromun studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
6 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 5
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses daromun is read from its arms, and is right about nine times in ten.
Testing it · 6
- Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma PatientsRecruitingPhase 2Philogen S.p.A.NCT06284590Written as L19IL2/L19TNF
- L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)RecruitingPhase 2Philogen S.p.A.NCT07227350Written as L19IL2/L19TNF
- L19IL2/L19TNF in Patients With Cutaneous Squamous Cell CarcinomaRecruitingPhase 2Philogen S.p.A.NCT07228442Written as L19IL2/L19TNF
- L19IL2/TNF in Patients With Basal Cell CarcinomaRecruitingPhase 2Philogen S.p.A.NCT07227870Written as L19IL2/L19TNF
- Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma PatientsRecruitingPhase 3Philogen S.p.A.NCT03567889Written as Daromun
- L19IL2/L19TNF in Skin Cancer PatientsRecruitingPhase 2Philogen S.p.A.NCT05329792Written as L19IL2/L19TNF
Codes
What other systems call daromun · ClinicalTrials.gg INT001325
- MeSH (NLM) C000706889daromunOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000706889 | daromun | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.